Summary
Global Markets Direct’s, ‘Alcoholic Hepatitis - Pipeline Review, H1 2016’, provides an overview of the Alcoholic Hepatitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis
- The report reviews pipeline therapeutics for Alcoholic Hepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Alcoholic Hepatitis therapeutics and enlists all their major and minor projects
- The report assesses Alcoholic Hepatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Alcoholic Hepatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alcoholic Hepatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Alfact Innovation
Conatus Pharmaceuticals Inc.
Generon (Shanghai) Corporation Ltd.
Immuron Limited
Intercept Pharmaceuticals, Inc.
Promethera Biosciences S.A.
Verlyx Pharma Inc.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Alcoholic Hepatitis Overview 6
Therapeutics Development 7
Pipeline Products for Alcoholic Hepatitis - Overview 7
Pipeline Products for Alcoholic Hepatitis - Comparative Analysis 8
Alcoholic Hepatitis - Therapeutics under Development by Companies 9
Alcoholic Hepatitis - Therapeutics under Investigation by Universities/Institutes 10
Alcoholic Hepatitis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Alcoholic Hepatitis - Products under Development by Companies 13
Alcoholic Hepatitis - Products under Investigation by Universities/Institutes 14
Alcoholic Hepatitis - Companies Involved in Therapeutics Development 15
Alfact Innovation 15
Conatus Pharmaceuticals Inc. 16
Generon (Shanghai) Corporation Ltd. 17
Immuron Limited 18
Intercept Pharmaceuticals, Inc. 19
Promethera Biosciences S.A. 20
Verlyx Pharma Inc. 21
Alcoholic Hepatitis - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
ALF-5755 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
emricasan - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
F-652 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
HepaStem - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
IMM-124E - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
obeticholic acid - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Oligonucleotide to Inhibit miRNA-155 for Alcoholic Liver Disease - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
pentamidine isethionate - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
PMKM-02G11 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Alcoholic Hepatitis - Recent Pipeline Updates 48
Alcoholic Hepatitis - Dormant Projects 63
Alcoholic Hepatitis - Product Development Milestones 64
Featured News & Press Releases 64
Nov 23, 2015: Generon Collaborating with Mayo Clinic to Initiate a Phase IIa Study with F-652, a First-in-Class Biologic, to Treat Patients with Alcoholic Hepatitis 64
Sep 11, 2013: Conatus Pharmaceuticals Initiates Phase 2b Trial of Emricasan in Acute-on-Chronic Liver Failure Patients 64
Sep 10, 2013: Conatus Pharmaceuticals' Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67
List of Tables
Number of Products under Development for Alcoholic Hepatitis, H1 2016 7
Number of Products under Development for Alcoholic Hepatitis - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Alcoholic Hepatitis - Pipeline by Alfact Innovation, H1 2016 15
Alcoholic Hepatitis - Pipeline by Conatus Pharmaceuticals Inc., H1 2016 16
Alcoholic Hepatitis - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2016 17
Alcoholic Hepatitis - Pipeline by Immuron Limited, H1 2016 18
Alcoholic Hepatitis - Pipeline by Intercept Pharmaceuticals, Inc., H1 2016 19
Alcoholic Hepatitis - Pipeline by Promethera Biosciences S.A., H1 2016 20
Alcoholic Hepatitis - Pipeline by Verlyx Pharma Inc., H1 2016 21
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Stage and Target, H1 2016 24
Number of Products by Stage and Mechanism of Action, H1 2016 26
Number of Products by Stage and Route of Administration, H1 2016 28
Number of Products by Stage and Molecule Type, H1 2016 30
Alcoholic Hepatitis Therapeutics - Recent Pipeline Updates, H1 2016 48
Alcoholic Hepatitis - Dormant Projects, H1 2016 63
List of Figures
Number of Products under Development for Alcoholic Hepatitis, H1 2016 7
Number of Products under Development for Alcoholic Hepatitis - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Top 10 Targets, H1 2016 23
Number of Products by Stage and Top 10 Targets, H1 2016 23
Number of Products by Top 10 Mechanism of Actions, H1 2016 25
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 25
Number of Products by Routes of Administration, H1 2016 27
Number of Products by Stage and Routes of Administration, H1 2016 27
Number of Products by Molecule Types, H1 2016 29
Number of Products by Stage and Molecule Types, H1 2016 29
